+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Adult Preventable Vaccines Market - Global Forecast 2026-2032- Product Image
Adult Preventable Vaccines Market - Global Forecast 2026-2032- Product Image
Sale

Adult Preventable Vaccines Market - Global Forecast 2026-2032

  • Report

  • 193 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6136452
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Adult Preventable Vaccines Market is projected to reach USD 9.64 Billion in 2026. It is expected to continue growing at a CAGR of 4.94%, reaching USD 12.84 Billion by 2032.

Adult Preventable Vaccines: Executive Overview

Adult preventable vaccines reduce the risk of infectious diseases that can cause severe illness, complications, disability, and avoidable deaths beyond childhood. The adult immunization agenda spans routine vaccination, catch-up programs, occupational protection, travel health, pregnancy-related protection, and vaccination for people with chronic conditions or weakened immune systems. Priorities differ by age, risk profile, national schedules, disease burden, and access to primary care.

Adult Immunization Is Shifting Toward Lifecourse Prevention

The landscape is moving from a child-centered model toward a lifecourse approach that includes adolescents, working-age adults, pregnant people, older adults, and medically vulnerable populations. Health systems are placing greater emphasis on opportunistic vaccination during primary-care visits, hospital discharge, pharmacy encounters, workplace programs, and chronic-disease management. Persistent barriers include missed recommendations, fragmented records, limited appointment capacity, uneven reimbursement, supply interruptions, and public concern about vaccine safety or necessity.

Artificial Intelligence Strengthens Identification, Outreach, and Delivery

Artificial intelligence can support adult vaccination by identifying people who are overdue, combining clinical and immunization-record data, prioritizing outreach, and tailoring reminders to language, age, risk, and care setting. Predictive tools may also assist inventory planning and help providers recognize vaccination opportunities during routine encounters. Effective use requires validated data, transparent clinical oversight, privacy safeguards, bias monitoring, and clear communication that preserves informed consent. AI should augment, rather than replace, public-health guidance and professional judgment.

Regional Insights: Uneven Access Shapes Adult Vaccination Priorities

North America generally benefits from established adult immunization guidance, electronic records, pharmacy delivery, and employer or insurer involvement, while access and uptake remain uneven across socioeconomic groups. Latin America is balancing stronger life-course immunization ambitions with fiscal constraints, geographic access challenges, and variable adult-program infrastructure. Europe combines mature national programs with differing schedules, reimbursement models, and uptake among older adults and risk groups. The Middle East is influenced by expatriate populations, travel requirements, chronic-disease burdens, and differences in national delivery capacity. Africa faces substantial opportunities to expand adult vaccination through primary care, maternal health, occupational programs, and targeted campaigns. Asia-Pacific contains highly diverse systems, from advanced digital and pharmacy networks to settings where rural access, cold-chain reliability, and workforce capacity remain central constraints.

Group Insights: Alliances Can Align Standards and Delivery

ASEAN countries can benefit from coordinated surveillance, shared procurement learning, and regionally adaptable communication while accounting for different health-system capacities. BRICS members have an opportunity to strengthen domestic production, evidence exchange, and adult vaccination access across large and diverse populations. The European Union can improve interoperability, cross-border recognition, and consistent communication while retaining national responsibility for schedules. G7 systems can advance evidence generation, resilient supply chains, and approaches for aging populations and high-risk adults. GCC countries can coordinate vaccination for mobile workforces, pilgrims, travelers, and people with chronic conditions. NATO members can connect routine immunization resilience with preparedness for outbreaks, military personnel, and essential workers.

Country Insights: National Delivery Models Require Tailored Priorities

Australia can build on primary-care and pharmacy delivery while addressing access for remote communities and older adults. Brazil and Mexico can use broad public-health networks to improve adult catch-up and risk-based vaccination. Canada and the United States can focus on reducing disparities across provinces, states, insurers, and underserved communities. China and India require approaches suited to large populations, varied local capacity, and diverse public-private delivery channels. France, Germany, Italy, Spain, and the United Kingdom can strengthen adult uptake through primary care, pharmacies, occupational health, and clearer age- and risk-based recommendations. Japan and South Korea can further integrate vaccination with healthy-aging and chronic-care services. Russia faces the need to sustain routine adult protection while adapting delivery to regional differences and public confidence considerations.

Leadership Priorities for Improving Adult Vaccine Uptake

Industry leaders should align products, evidence, and services with clearly defined adult risk groups and national recommendations. They should support provider education, simplified eligibility tools, reminder-recall systems, interoperable records, and convenient administration through pharmacies, workplaces, community clinics, and primary care. Partnerships with public-health authorities and employers can improve reach, while transparent safety communication and culturally appropriate engagement can strengthen confidence. Operationally, leaders should monitor supply continuity, cold-chain performance, missed opportunities, completion rates, equity gaps, and outcomes by age, geography, and clinical risk. AI initiatives should begin with measurable use cases, human oversight, and rigorous governance.

Research Methodology for the Adult Preventable Vaccines Assessment

The assessment uses a structured review of adult immunization policy, public-health guidance, epidemiological evidence, delivery models, access barriers, technology applications, and regional and national health-system characteristics. Findings are organized across the required regions, country groups, and countries to distinguish common structural themes from local implementation conditions. The approach emphasizes verified public sources and established evidence, avoids unsupported quantitative claims, and treats differences in schedules, eligibility, reimbursement, surveillance, and delivery capacity as essential context. Interpretations should be updated as recommendations, disease patterns, technologies, and health-system policies evolve.

Conclusion: Make Adult Vaccination a Routine Part of Lifecourse Care

Adult preventable vaccines are most effective as part of integrated, convenient, and trusted health services rather than isolated campaigns. Progress depends on consistent recommendations, reliable supply, accessible administration, accurate records, proactive reminders, and targeted support for underserved populations. Health-system leaders, providers, employers, technology developers, and public authorities can accelerate improvement by combining evidence-based policy with practical delivery innovations and accountable data use. A sustained lifecourse strategy can help make vaccination a normal component of prevention, healthy aging, and preparedness.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Adult Preventable Vaccines Market, by Vaccine Type
7.1. Introduction
7.2. Hepatitis B Vaccine
7.2.1. Engerix-B
7.2.2. Heplisav-B
7.2.3. Recombivax HB
7.3. HPV Vaccine
7.3.1. Cervarix
7.3.2. Gardasil
7.3.3. Gardasil 9
7.4. Influenza Vaccine
7.4.1. Adjuvanted
7.4.2. Quadrivalent
7.4.3. Trivalent
7.5. Meningococcal Vaccine
7.5.1. Menactra
7.5.2. MenQuadfi
7.5.3. Menveo
7.6. Pneumococcal Vaccine
7.6.1. PCV13
7.6.2. PPSV23
7.7. Shingles Vaccine
7.7.1. Shingrix
7.7.2. Zostavax
7.8. Tdap Vaccine
7.8.1. Adacel
7.8.2. Boostrix
8. Adult Preventable Vaccines Market, by Technology Platform
8.1. Introduction
8.2. Conjugate
8.3. Inactivated
8.4. Live Attenuated
8.5. Recombinant
9. Adult Preventable Vaccines Market, by Payment Type
9.1. Introduction
9.2. Government Funded
9.3. Out Of Pocket
9.4. Private Insurance
10. Adult Preventable Vaccines Market, by Distribution Channel
10.1. Introduction
10.2. Clinic
10.3. Hospital
10.4. Pharmacy
10.5. Public Health Facility
11. Adult Preventable Vaccines Market, by Region
11.1. Introduction
11.2. Asia-Pacific
11.3. North America
11.4. Latin America
11.5. Europe
11.6. Middle East
11.7. Africa
12. Adult Preventable Vaccines Market, by Group
12.1. Introduction
12.2. ASEAN
12.3. GCC
12.4. European Union
12.5. BRICS
12.6. G7
12.7. NATO
13. Adult Preventable Vaccines Market, by Country
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. United Kingdom
13.7. Germany
13.8. France
13.9. Russia
13.10. Italy
13.11. Spain
13.12. China
13.13. India
13.14. Japan
13.15. Australia
13.16. South Korea
14. Competitive Landscape
14.1. Market Share Analysis, 2025
14.2. Market Concentration Analysis, 2025
14.2.1. Concentration Ratio (CR)
14.2.2. Herfindahl Hirschman Index (HHI)
14.3. Recent Developments & Impact Analysis, 2025
14.4. Product Portfolio Analysis, 2025
14.5. Benchmarking Analysis, 2025
15. Company Profiles
15.1. AstraZeneca plc
15.2. Bharat Biotech International Limited
15.3. BioNTech SE
15.4. CanSino Biologics Inc.
15.5. CSL Limited
15.6. CureVac N.V.
15.7. GlaxoSmithKline plc
15.8. Johnson & Johnson
15.9. Merck & Co. Inc.
15.10. Moderna Inc.
15.11. Novavax Inc.
15.12. Pfizer Inc.
15.13. Sanofi S.A.
15.14. Seqirus
15.15. Serum Institute of India Pvt. Ltd.
15.16. Sinopharm Group Co. Ltd.
15.17. Sinovac Biotech Ltd.
16. Key Experts
LIST OF FIGURES
FIGURE 1. Global Adult Preventable Vaccines Market, Years Considered for the Study
FIGURE 2. Global Adult Preventable Vaccines Market, Research Design
FIGURE 3. Global Adult Preventable Vaccines Market, Research Framework
FIGURE 4. Global Adult Preventable Vaccines Market, Data Triangulation
FIGURE 5. Global Adult Preventable Vaccines Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Adult Preventable Vaccines Market Size, by Vaccine Type, 2025 vs 2032 (%)
FIGURE 7. Global Adult Preventable Vaccines Market Size, by Vaccine Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Adult Preventable Vaccines Market Size, by Technology Platform, 2025 vs 2032 (%)
FIGURE 9. Global Adult Preventable Vaccines Market Size, by Technology Platform, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Adult Preventable Vaccines Market Size, by Payment Type, 2025 vs 2032 (%)
FIGURE 11. Global Adult Preventable Vaccines Market Size, by Payment Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Adult Preventable Vaccines Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 13. Global Adult Preventable Vaccines Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Adult Preventable Vaccines Market Size, by Region, 2025 vs 2032 (%)
FIGURE 15. Global Adult Preventable Vaccines Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Adult Preventable Vaccines Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 17. Global Adult Preventable Vaccines Market Size, by Country, 2025 vs 2032 (%)
FIGURE 18. Global Adult Preventable Vaccines Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global Adult Preventable Vaccines Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Adult Preventable Vaccines Market Segmentation & Coverage
TABLE 2. Global Adult Preventable Vaccines Market Size, 2017-2032 (USD Million)
TABLE 3. Global Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 4. Global Hepatitis B Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Hepatitis B Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Hepatitis B Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Engerix-B Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Engerix-B Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Engerix-B Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Heplisav-B Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Heplisav-B Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Heplisav-B Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Recombivax HB Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Recombivax HB Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Recombivax HB Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global HPV Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global HPV Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global HPV Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Cervarix Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Cervarix Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Cervarix Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Gardasil Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Gardasil Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Gardasil Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Gardasil 9 Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Gardasil 9 Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Gardasil 9 Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Influenza Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Influenza Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Influenza Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Adjuvanted Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Adjuvanted Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Adjuvanted Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Quadrivalent Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Quadrivalent Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Quadrivalent Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Trivalent Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Trivalent Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Trivalent Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Meningococcal Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Meningococcal Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Meningococcal Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Menactra Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Menactra Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Menactra Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global MenQuadfi Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global MenQuadfi Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global MenQuadfi Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Menveo Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Menveo Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Menveo Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global Pneumococcal Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 53. Global Pneumococcal Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 54. Global Pneumococcal Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 55. Global PCV13 Market Size, by Region, 2017-2032 (USD Million)
TABLE 56. Global PCV13 Market Size, by Group, 2017-2032 (USD Million)
TABLE 57. Global PCV13 Market Size, by Country, 2017-2032 (USD Million)
TABLE 58. Global PPSV23 Market Size, by Region, 2017-2032 (USD Million)
TABLE 59. Global PPSV23 Market Size, by Group, 2017-2032 (USD Million)
TABLE 60. Global PPSV23 Market Size, by Country, 2017-2032 (USD Million)
TABLE 61. Global Shingles Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 62. Global Shingles Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 63. Global Shingles Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 64. Global Shingrix Market Size, by Region, 2017-2032 (USD Million)
TABLE 65. Global Shingrix Market Size, by Group, 2017-2032 (USD Million)
TABLE 66. Global Shingrix Market Size, by Country, 2017-2032 (USD Million)
TABLE 67. Global Zostavax Market Size, by Region, 2017-2032 (USD Million)
TABLE 68. Global Zostavax Market Size, by Group, 2017-2032 (USD Million)
TABLE 69. Global Zostavax Market Size, by Country, 2017-2032 (USD Million)
TABLE 70. Global Tdap Vaccine Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Tdap Vaccine Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Tdap Vaccine Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Adacel Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Adacel Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Adacel Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Boostrix Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Global Boostrix Market Size, by Group, 2017-2032 (USD Million)
TABLE 78. Global Boostrix Market Size, by Country, 2017-2032 (USD Million)
TABLE 79. Global Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 80. Global Conjugate Market Size, by Region, 2017-2032 (USD Million)
TABLE 81. Global Conjugate Market Size, by Group, 2017-2032 (USD Million)
TABLE 82. Global Conjugate Market Size, by Country, 2017-2032 (USD Million)
TABLE 83. Global Inactivated Market Size, by Region, 2017-2032 (USD Million)
TABLE 84. Global Inactivated Market Size, by Group, 2017-2032 (USD Million)
TABLE 85. Global Inactivated Market Size, by Country, 2017-2032 (USD Million)
TABLE 86. Global Live Attenuated Market Size, by Region, 2017-2032 (USD Million)
TABLE 87. Global Live Attenuated Market Size, by Group, 2017-2032 (USD Million)
TABLE 88. Global Live Attenuated Market Size, by Country, 2017-2032 (USD Million)
TABLE 89. Global Recombinant Market Size, by Region, 2017-2032 (USD Million)
TABLE 90. Global Recombinant Market Size, by Group, 2017-2032 (USD Million)
TABLE 91. Global Recombinant Market Size, by Country, 2017-2032 (USD Million)
TABLE 92. Global Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 93. Global Government Funded Market Size, by Region, 2017-2032 (USD Million)
TABLE 94. Global Government Funded Market Size, by Group, 2017-2032 (USD Million)
TABLE 95. Global Government Funded Market Size, by Country, 2017-2032 (USD Million)
TABLE 96. Global Out Of Pocket Market Size, by Region, 2017-2032 (USD Million)
TABLE 97. Global Out Of Pocket Market Size, by Group, 2017-2032 (USD Million)
TABLE 98. Global Out Of Pocket Market Size, by Country, 2017-2032 (USD Million)
TABLE 99. Global Private Insurance Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Global Private Insurance Market Size, by Group, 2017-2032 (USD Million)
TABLE 101. Global Private Insurance Market Size, by Country, 2017-2032 (USD Million)
TABLE 102. Global Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 103. Global Clinic Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Clinic Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Clinic Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Hospital Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Hospital Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Hospital Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global Pharmacy Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global Pharmacy Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global Pharmacy Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Public Health Facility Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Public Health Facility Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Public Health Facility Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Adult Preventable Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Asia-Pacific Adult Preventable Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 117. Asia-Pacific Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 118. Asia-Pacific Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 119. Asia-Pacific Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 120. Asia-Pacific Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 121. Asia-Pacific Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 122. Asia-Pacific Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 123. Asia-Pacific Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 124. Asia-Pacific Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 125. Asia-Pacific Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 126. Asia-Pacific Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 127. Asia-Pacific Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 128. North America Adult Preventable Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. North America Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 130. North America Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 131. North America Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 132. North America Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 133. North America Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 134. North America Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 135. North America Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 136. North America Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 137. North America Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 138. North America Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 139. North America Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 140. Latin America Adult Preventable Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 141. Latin America Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 142. Latin America Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 143. Latin America Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 144. Latin America Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 145. Latin America Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 146. Latin America Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 147. Latin America Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 148. Latin America Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 149. Latin America Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 150. Latin America Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 151. Latin America Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 152. Europe Adult Preventable Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 153. Europe Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 154. Europe Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 155. Europe Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 156. Europe Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 157. Europe Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 158. Europe Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 159. Europe Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 160. Europe Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 161. Europe Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 162. Europe Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 163. Europe Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 164. Middle East Adult Preventable Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 165. Middle East Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 166. Middle East Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 167. Middle East Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 168. Middle East Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 169. Middle East Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 170. Middle East Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 171. Middle East Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 172. Middle East Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 173. Middle East Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 174. Middle East Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 175. Middle East Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 176. Africa Adult Preventable Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 177. Africa Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 178. Africa Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 179. Africa Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 180. Africa Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 181. Africa Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 182. Africa Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 183. Africa Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 184. Africa Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 185. Africa Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 186. Africa Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 187. Africa Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. Global Adult Preventable Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 189. ASEAN Adult Preventable Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 190. ASEAN Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 191. ASEAN Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 192. ASEAN Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 193. ASEAN Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 194. ASEAN Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 195. ASEAN Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 196. ASEAN Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 197. ASEAN Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 198. ASEAN Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 199. ASEAN Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 200. ASEAN Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 201. GCC Adult Preventable Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 202. GCC Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 203. GCC Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 204. GCC Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 205. GCC Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 206. GCC Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 207. GCC Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 208. GCC Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 209. GCC Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 210. GCC Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 211. GCC Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 212. GCC Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 213. European Union Adult Preventable Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 214. European Union Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 215. European Union Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 216. European Union Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 217. European Union Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 218. European Union Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 219. European Union Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 220. European Union Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 221. European Union Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 222. European Union Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 223. European Union Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 224. European Union Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 225. BRICS Adult Preventable Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 226. BRICS Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 227. BRICS Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 228. BRICS Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 229. BRICS Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 230. BRICS Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 231. BRICS Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 232. BRICS Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 233. BRICS Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 234. BRICS Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 235. BRICS Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 236. BRICS Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 237. G7 Adult Preventable Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 238. G7 Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 239. G7 Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 240. G7 Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 241. G7 Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 242. G7 Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 243. G7 Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 244. G7 Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 245. G7 Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 246. G7 Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 247. G7 Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 248. G7 Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 249. NATO Adult Preventable Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 250. NATO Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 251. NATO Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 252. NATO Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 253. NATO Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 254. NATO Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 255. NATO Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 256. NATO Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 257. NATO Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 258. NATO Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 259. NATO Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 260. NATO Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 261. Global Adult Preventable Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 262. United States Adult Preventable Vaccines Market Size, 2017-2032 (USD Million)
TABLE 263. United States Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 264. United States Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 265. United States Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 266. United States Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 267. United States Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 268. United States Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 269. United States Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 270. United States Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 271. United States Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 272. United States Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 273. United States Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 274. Canada Adult Preventable Vaccines Market Size, 2017-2032 (USD Million)
TABLE 275. Canada Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 276. Canada Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 277. Canada Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 278. Canada Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 279. Canada Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 280. Canada Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 281. Canada Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 282. Canada Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 283. Canada Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 284. Canada Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 285. Canada Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 286. Mexico Adult Preventable Vaccines Market Size, 2017-2032 (USD Million)
TABLE 287. Mexico Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 288. Mexico Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 289. Mexico Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 290. Mexico Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 291. Mexico Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 292. Mexico Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 293. Mexico Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 294. Mexico Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 295. Mexico Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 296. Mexico Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 297. Mexico Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 298. Brazil Adult Preventable Vaccines Market Size, 2017-2032 (USD Million)
TABLE 299. Brazil Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 300. Brazil Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 301. Brazil Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 302. Brazil Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 303. Brazil Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 304. Brazil Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 305. Brazil Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 306. Brazil Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 307. Brazil Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 308. Brazil Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 309. Brazil Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 310. United Kingdom Adult Preventable Vaccines Market Size, 2017-2032 (USD Million)
TABLE 311. United Kingdom Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 312. United Kingdom Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 313. United Kingdom Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 314. United Kingdom Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 315. United Kingdom Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 316. United Kingdom Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 317. United Kingdom Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 318. United Kingdom Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 319. United Kingdom Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 320. United Kingdom Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 321. United Kingdom Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 322. Germany Adult Preventable Vaccines Market Size, 2017-2032 (USD Million)
TABLE 323. Germany Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 324. Germany Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 325. Germany Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 326. Germany Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 327. Germany Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 328. Germany Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 329. Germany Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 330. Germany Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 331. Germany Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 332. Germany Adult Preventable Vaccines Market Size, by Payment Type, 2017-2032 (USD Million)
TABLE 333. Germany Adult Preventable Vaccines Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 334. France Adult Preventable Vaccines Market Size, 2017-2032 (USD Million)
TABLE 335. France Adult Preventable Vaccines Market Size, by Vaccine Type, 2017-2032 (USD Million)
TABLE 336. France Adult Preventable Vaccines Market Size, by Hepatitis B Vaccine, 2017-2032 (USD Million)
TABLE 337. France Adult Preventable Vaccines Market Size, by HPV Vaccine, 2017-2032 (USD Million)
TABLE 338. France Adult Preventable Vaccines Market Size, by Influenza Vaccine, 2017-2032 (USD Million)
TABLE 339. France Adult Preventable Vaccines Market Size, by Meningococcal Vaccine, 2017-2032 (USD Million)
TABLE 340. France Adult Preventable Vaccines Market Size, by Pneumococcal Vaccine, 2017-2032 (USD Million)
TABLE 341. France Adult Preventable Vaccines Market Size, by Shingles Vaccine, 2017-2032 (USD Million)
TABLE 342. France Adult Preventable Vaccines Market Size, by Tdap Vaccine, 2017-2032 (USD Million)
TABLE 343. France Adult Preventable Vaccines Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 344. France Adult Preventable Vaccines Market S

Companies Mentioned

  • AstraZeneca plc
  • Bharat Biotech International Limited
  • BioNTech SE
  • CanSino Biologics Inc.
  • CSL Limited
  • CureVac N.V.
  • GlaxoSmithKline plc
  • Johnson & Johnson
  • Merck & Co. Inc.
  • Moderna Inc.
  • Novavax Inc.
  • Pfizer Inc.
  • Sanofi S.A.
  • Seqirus
  • Serum Institute of India Pvt. Ltd.
  • Sinopharm Group Co. Ltd.
  • Sinovac Biotech Ltd.

Related Topics

Related Reports

Adult Vaccines Market - Global Forecast 2026-2032 - Product Image

Adult Vaccines Market - Global Forecast 2026-2032

  • Report
  • 185 Pages
  • Global
From
Pediatric Preventable Vaccine Market - Global Forecast 2026-2032 - Product Image

Pediatric Preventable Vaccine Market - Global Forecast 2026-2032

  • Report
  • 196 Pages
  • Global
From
Preventable Vaccines - Global Strategic Business Report - Product Image

Preventable Vaccines - Global Strategic Business Report

  • Report
  • 391 Pages
  • Global
From
Adult Vaccines Market Report by Disease wise and Countries and Companies Analysis 2026-2034 - Product Image

Adult Vaccines Market Report by Disease wise and Countries and Companies Analysis 2026-2034

  • Report
  • 200 Pages
  • Global
From
Adult Vaccines Market - Global Strategic Business Report - Product Image

Adult Vaccines Market - Global Strategic Business Report

  • Report
  • 377 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.